BOUCHERVILLE, QC, March 31, 2016 (GLOBE NEWSWIRE) — Sandoz Canada Inc. announced the launch of Prtobramycin Inhalation Solution, an authorized generic version of PrTOBI*, currently marketed by Novartis Pharmaceuticals Canada Inc. PrTOBRAMYCIN INHALATION SOLUTION, a respiratory antibiotic, is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. “We are proud to bring an authorized generic version of PrTOBI* to Canadian patients with cystic fibrosis and suffering from chronic pulmonary infections,” said Michel Robidoux, President and General Manager of Sandoz Canada Inc. “This launch is in line with our commitment to offer high-quality, affordable […]